



0300

PF-0027US

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed to :
Assistant Co, Washington, D.C. 20231 on May 1, 1995.

By: Melissa K. Luebke
Melissa K. Luebke

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: ROGER COLEMAN, ET AL.)
)
Filed: February 17, 1995) Examiner: To Be Assigned
)
Serial No.: 08/390,740) Art Unit: To Be Assigned
)
Title: **NEW CHEMOKINES EXPRESSED IN**)
 PANCREAS)
)
)
)

Palo Alto, California
May 1, 1995

Honorable Commissioner of Patents
and Trademarks
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the duty of disclosure under 37 C.F.R. §§ 1.56, 1.98 and 1.99,
Applicants wish to bring to the attention of the U.S. Patent and Trademark Office the references
listed below and on the enclosed Form PTO-1449.

1. Jan Vilcek, et al., Immunology of Cytokines, The Cytokine Handbook, Academic
Press, Copyright 1991, Chapter 1, pp. 1-17.

2. Alan R. Shaw, Molecular Biology of Cytokines, The Cytokine Handbook, Academic Press, Copyright 1991, Chapter 2, pp. 20-46.
3. Jacques Banchereau, Interleukin-4, The Cytokine Handbook, Academic Press, Copyright 1991, Chapter 6, pp. 120-148.
4. Thomas J. Schall, The Chemokines, The Chemokine Handbook, Academic Press, 1994, (Targets for Therapeutics Development, Symposium held at Washington Vista, Washington, DC, September 19-20, 1994), Second Edition, pp. 180-272.

Citation of the above documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. Citation of the above documents shall not be construed as a representation that a search has been made. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner and that an initialed copy of the Form PTO-1449 be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.

The Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Deposit Account No. 09-0108. A duplicate copy of this communication is enclosed for accounting purposes.

If there are any questions regarding the above, the Examiner is invited to call the undersigned attorney at 415-855-0555.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Date: May 1, 1995

Barbara J. Luther

Barbara J. Luther
Attorney for Applicants
Reg. No.: 33,954

3330 Hillview Avenue
Palo Alto, CA 94304
Tel: 415-855-0555
Fax: 415-852-0195